AstraZeneca To Co-Promote Abraxis’ Paclitaxel
This article was originally published in The Pink Sheet Daily
Executive Summary
Abraxis bolsters the resources behind Abraxane by doubling its sales force and acquiring Pfizer’s manufacturing facility in Puerto Rico.
You may also be interested in...
Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Celgene is acquiring Abraxane developer Abraxis Biosciences and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015
Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Celgene is acquiring Abraxane developer Abraxis Biosciences and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015
FDA Approves APP's Abraxane Paclitaxel Formulation
American Pharmaceutical Partners will submit survival data and pharmacokinetic data in subjects with hepatic impairment for Abraxane as part of the company's Phase IV commitments. APP hopes to position Abraxane as safer and more effective than Bristol's Taxol and paclitaxel generics.